Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laina D Mercer

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Lancet (London, England)|November 17, 2025
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 studyRobert W Frenck, Abdi Naficy, Jodi Feser, et al.
The Lancet. Infectious Diseases|May 9, 2024
Genotypic analysis of RTS,S/AS01<sub>E</sub> malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trialMichal Juraska, Angela M Early, Li Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Lancet (London, England)|November 17, 2025
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 studyRobert W Frenck, Abdi Naficy, Jodi Feser, et al.
The Lancet. Infectious Diseases|May 9, 2024
Genotypic analysis of RTS,S/AS01<sub>E</sub> malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trialMichal Juraska, Angela M Early, Li Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Pageof 5